The new Health and Care Bill gives NHS Digital powers to create a new ‘medicine registry’
The bill, published earlier this month, will allow NHS Digital to collect a range of information about the use of medicines and their effects in the UK and hold this data in one or more information system(s). The MHRA would be able to then use the information held in an information system to establish and maintain comprehensive UK-wide medicines registries.
“This would improve post-market surveillance on the use [of] medicines. For example, where a safety issue has led to the introduction of measures to minimise risk to patients, registries would facilitate the early identification and investigation of potential noncompliance so that additional action can be taken by regulators in conjunction with health service providers at a national, local, or individual patient level.”
The notes added the power is “restricted to purposes relating to the safety, quality and efficacy of human medicines and the improvement of clinical decision-making in relation to human medicines”.
Anybody who inappropriately shares NHS data collected for the new registry could face a fine and a prison sentence.
What does this mean for patient safety? What impact will this has on the NHS and for private providers?
Registered address:
Patient Safety Learning, China Works SB203, 100 Black Prince Road Vauxhall, London, SE1 7SJ
Important Information
We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.
The new Health and Care Bill gives NHS Digital powers to create a new ‘medicine registry’
The bill, published earlier this month, will allow NHS Digital to collect a range of information about the use of medicines and their effects in the UK and hold this data in one or more information system(s). The MHRA would be able to then use the information held in an information system to establish and maintain comprehensive UK-wide medicines registries.
“This would improve post-market surveillance on the use [of] medicines. For example, where a safety issue has led to the introduction of measures to minimise risk to patients, registries would facilitate the early identification and investigation of potential noncompliance so that additional action can be taken by regulators in conjunction with health service providers at a national, local, or individual patient level.”
The notes added the power is “restricted to purposes relating to the safety, quality and efficacy of human medicines and the improvement of clinical decision-making in relation to human medicines”.
Anybody who inappropriately shares NHS data collected for the new registry could face a fine and a prison sentence.
What does this mean for patient safety? What impact will this has on the NHS and for private providers?
@Helena Gregory. @Kathryn Howard, @Kristen, @Alison Smith, @Phaeds, @CYC, @Dakota, @Steve Turner